PubMed
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 56% · Mixed 28% · Unfavorable overall 16%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 200–400 mcg
Reports span 10–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 66% said they felt similar to their last entry, 42% more positive, and 16% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 16 days · Based on 165 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 51% · Mixed 32% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 25–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 329 repeat reporters
Published sources linked on the BPC-157 (Oral) and TB-500 Fragment wiki pages.
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011
PubMed
Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018
PubMed
Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
PubMed
Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026